GLP-1 Receptor Agonist Use Associated With Measurable Decline in Physical Activity, Wearable Data Shows

A new study shows that adults with obesity lower their physical activity after starting GLP-1 receptor agonist therapy. Researchers looked at data from wearable fitness trackers and electronic health records. They found decreases in daily step counts and moderate-to-vigorous physical activity. These results challenge the common belief that weight loss from medication leads to more movement.

The retrospective pre-post cohort study used data from the National Institutes of Health. Out of 1,950 adults with obesity who began the therapy, 753 participants provided enough wearable device data. This group was mostly female with a mean age of 52.7 years. The researchers compared activity metrics before and after treatment started.

On average, daily step counts dropped from 5,047 to 4,487 after treatment began. Moderate-to-vigorous physical activity minutes decreased from 28 to 22 per day during the same period. The largest reductions occurred among men and people with musculoskeletal pain. Age and history of heart failure did not significantly affect these outcomes.

GLP-1 receptor agonists lower both fat and lean muscle mass. Therefore, physical activity plays an important protective role for patients using these drugs. Programs that promote physical activity should go hand in hand with medication for obesity. Exercise is essential for this group.

This study is the first major analysis to use wearable fitness device data for this population. This method improves real-world relevance because data from devices reflect actual behavior. However, the retrospective design limits the ability to determine cause and effect. Confounding factors in observational data can’t be completely ruled out.

The clinical implications reach beyond individual patient care. Prescriptions for these medications are growing in obesity and diabetes treatment. Given this, current treatment plans may need to include structured physical activity components. Preserving muscle mass directly impacts metabolic health and long-term function.

The lack of increased spontaneous activity represents a significant gap in routine care. Doctors prescribing these medications should think about adding exercise counseling to treatment plans. Referring patients for formal rehabilitation is another way to help prevent muscle loss. These steps can improve overall patient care.